Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib.

被引：0
|
作者：
Starodub, Alexander
Milhem, Mohammed M.
Pennington, Kenneth Lee
Kio, Ebenezer A.
Bruetman, Daniel
Thorne, Tracy
Hickingbottom, Barbara
Kroll, Stew
机构：
[1] Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN USA
[2] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
[3] Goshen Ctr Canc Care, Goshen, IN USA
[4] Ctr Canc Care Goshen, Goshen, IN USA
[5] Threshold Pharmaceut Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15557
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of TH-302, an investigational hypoxia-targeted drug, in combination with sunitinib.
    Starodub, Alexander
    Vaena, Daniel
    Pennington, Kenneth L.
    Kio, Ebenezer A.
    Bruetman, Daniel
    Thorne, Tracy
    Kroll, Stewart
    Milhem, Mohammed M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [2] Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302.
    Meadows, Kellen L.
    Lee, Paula H.
    Riedel, Richard F.
    Morse, Michael A.
    Uronis, Hope E.
    Blobe, Gerard G.
    George, Daniel J.
    Crawford, Jeffrey
    Hurwitz, Herbert I.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [3] Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma
    Ghobrial, Irene M.
    Laubach, Jacob
    Armand, Philippe
    Boswell, Erica
    Hanlon, Courtney
    Chuma, Stacey
    Chu, Esther Dawn
    Handisides, Damian
    Kroll, Stew
    Hickingbottom, Barbara
    Anderson, Kenneth Carl
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Laubach, Jacob P.
    Raje, Noopur
    Armand, Philippe
    Schlossman, Robert L.
    Boswell, Erica N.
    Hanlon, Courtney
    Chuma, Stacey
    Handisides, Damian R.
    Kroll, Stewart
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2013, 122 (21)
  • [5] Response biomarkers for the hypoxia-targeted drug TH-302: imaging, plasma, and tissue
    Sun, Jessica D.
    Liu, Qian
    Ahluwalia, Dharmendra
    Wang, Yan
    Szardenings, Anna-Katrin
    Gomez, Luis F.
    Kolb, Hartmuth
    Pierce, Karen A.
    Brown-Shimer, Sheryl
    Carney, Walter A.
    Hart, Charles P.
    CANCER RESEARCH, 2013, 73 (08)
  • [6] PRELIMINARY SAFETY AND EFFICACY OF TH-302, AN INVESTIGATIONAL HYPOXIA-TARGETED DRUG, AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM)
    Laubach, J. P.
    Raje, N.
    Armand, P.
    Schlossman, R. L.
    Rosenblatt, J.
    Matous, J. V.
    Hedlund, J.
    Martin, M.
    Reynolds, C.
    Shain, K. H.
    Zackon, I.
    Stampleman, L.
    Boswell, E. N.
    Chuma, S.
    Liguori, R.
    Handisides, D. R.
    Kroll, S.
    Anderson, K. C.
    Richardson, P. G.
    Ghobrial, I. M.
    HAEMATOLOGICA, 2014, 99 : 108 - 109
  • [7] Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).
    Laubach, Jacob
    Raje, Noopur S.
    Armand, Philippe
    Schlossman, Robert L.
    Rosenblatt, Jacalyn
    Matous, Jeffrey
    Hedlund, Jacquelyn Ann
    Martin, Michael Gary
    Reynolds, Craig H.
    Shain, Kenneth H.
    Zackon, Ira
    Stampleman, Laura
    Boswell, Erica
    Chuma, Stacey
    Liguori, Rebecca
    Handisides, Damian
    Kroll, Stew
    Anderson, Kenneth Carl
    Richardson, Paul G.
    Ghobrial, Irene M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models
    Kumar, Sushil
    Sun, Jessica D.
    Zhang, Libo
    Mokhtari, Reza Bayat
    Wu, Bing
    Meng, Fanying
    Liu, Qian
    Bhupathi, Deepthi
    Wang, Yan
    Yeger, Herman
    Hart, Charles
    Baruchel, Sylvain
    TRANSLATIONAL ONCOLOGY, 2018, 11 (04): : 911 - 919
  • [9] A first-in-man phase I study of TH-302, a hypoxia-activated cytotoxic prodrug
    Weiss, G. J.
    Infante, J. R.
    Borad, M.
    Langmuir, V. K.
    Kroll, S.
    Jung, D.
    Tibes, R.
    Chiorean, E. G.
    Jones, S. F.
    Burris, H. A.
    EJC SUPPLEMENTS, 2008, 6 (12): : 129 - 130
  • [10] Phase 1/2 study of investigational hypoida-targeted drug, TH-302, and bevacizumab (hey) in recurrent glioblastoma (GBM) following bey failure
    Brenner, Andrew Jacob
    Sun, Jessica D.
    Floyd, John
    Hart, Charles P.
    Eng, Clarence
    Kroll, Stew
    Flchtel, Lisa
    Gruslova, Aleksandra
    Lodl, Alessla
    Tizianl, Stefano
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345